Zobrazeno 1 - 10
of 124
pro vyhledávání: ''
Autor:
Patrick Chaftari, Ray Y Hachem, Alexandre E. Malek, Natalie Dailey Garnes, Ying Jiang, Victor E. Mulanovich, Anne Marie Chaftari, Hiba dagher, Sai Ching J. Yeung, Issam I Raad
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8475-8482 (2021)
Cancer Medicine
Cancer Medicine
Background The Multinational Association for Supportive Care in Cancer (MASCC) risk index has been utilized to determine the risk for poor clinical outcomes in patients with febrile neutropenia (FN) in an emergency center (EC). However, this index co
Autor:
Qiong Lyu, Jian Zhang, Peng Luo, Ting Wei, Weimin Ding, Linlang Guo, Weiliang Zhu, Qiongyao Wang, Manming Cao
Publikováno v:
Cancer Medicine, Vol 10, Iss 21, Pp 7863-7876 (2021)
Cancer Medicine
Cancer Medicine
Background The majority of patients with small‐cell lung cancer (SCLC) show a good response in the early stages of treatment, but more than 90% of patients will develop drug resistance. Therefore, biomarkers are urgently needed to identify patients
Autor:
Lanfang Li, Xianhuo Wang, Jin He, Sicong Zhang, Bin Meng, Jing Zhao, Xiaoxing Su, Shiyong Zhou, Lihua Qiu, Hengqi Liu, Tingting Zhang, Huilai Zhang, Xiubao Ren, Zhengzi Qian, Haifei Zhou, Xianming Liu, Wenchen Gong
Publikováno v:
British Journal of Haematology. 196:617-628
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogenous malignancy, early identification of patients for relapse remains challenging. The potential to non-invasively monitor tumour evolutionary dynamics of DLBCL needs to be further established
Autor:
Serena K. Wolfe, David J. Beebe, Jamie M. Sperger, Jennifer L. Schehr, Erika Heninger, Toni K. Choueri, Xiao X. Wei, Joshua A. Desotelle, Charlotte N. Stahlfeld, Waddah Arafat, Joshua M. Lang, John A. Steinharter, Hamid Emamekhoo, Rana R. McKay, E. Jason Abel, Anupama Singh, Matthew C. Mannino, Tamara S. Rodems, David J. Niles, Rory M. Bade, Benjamin K. Gibbs
Publikováno v:
Molecular Oncology, Vol 15, Iss 9, Pp 2330-2344 (2021)
Molecular Oncology
Molecular Oncology
Although therapeutic options for patients with advanced renal cell carcinoma (RCC) have increased in the past decade, no biomarkers are yet available for patient stratification or evaluation of therapy resistance. Given the dynamic and heterogeneous
Publikováno v:
IUBMB Life. 73:1334-1347
HIF-2α selective inhibitor showed successful efficacy in sensitive clear cell renal cell carcinoma (ccRCC) presenting higher levels of HIF-2α compared to resistant tumors with low level of HIF-2α (negative HIF-2α ccRCC). Currently, negative HIF-2
Autor:
Takao Takahashi, Kazuhiro Yoshida, Nobuhisa Matsuhashi, Nobuhiko Sugito, Yukihiro Akao, Masahiro Fukada, Kazuki Heishima
Publikováno v:
Cancer Science
Cancer‐related microRNAs (miRNAs) are emerging as promising and noninvasive biomarkers for colorectal cancer (CRC). This study aimed to investigate the usefulness of postoperative changes in plasma miR21‐5p levels for recurrence and progressive d
MicroRNAs in blood act as biomarkers of colorectal cancer and indicate potential therapeutic targets
Autor:
Jörg D. Hoheisel, Karl J. Oldhafer, Andrea S. Bauer, Hauke Weilert, Chaoyang Zhang, Axel Stang, Michael J. Lipp
Publikováno v:
Molecular Oncology
Molecular Oncology, Vol 15, Iss 9, Pp 2480-2490 (2021)
Molecular Oncology, Vol 15, Iss 9, Pp 2480-2490 (2021)
Association studies have linked alterations of blood‐derived microRNAs (miRNAs) with colorectal cancer (CRC). Here, we performed a microarray‐based comparison of the profiles of 2549 miRNAs in 80 blood samples from healthy donors and patients wit
Autor:
Tomoki Taki, Yoshie Murakami, Satoko Imai, Aoi Ebata, Masashi Akiyama, Honami Akanabe, Toru Urata, Shoichiro Mori, Kenji Yokota, Mao Okumura
Publikováno v:
Cancer Science
Angiosarcoma of the head and neck (ASHN) is one of the most aggressive malignancies of the skin, but the prognostic factors are not well known because of its rarity. Recently, high plasma fibrinogen levels were reported to predict poor prognosis in s
Diagnostic and prognostic value of stem cell factor plasma level in glioblastoma multiforme patients
Publikováno v:
Cancer Medicine, Vol 10, Iss 15, Pp 5154-5162 (2021)
Cancer Medicine
Cancer Medicine
Background Investigation of novel blood‐circulating agents as potential biomarkers for glioblastoma multiforme (GBM) patients’ diagnosis and monitoring has gained lots of attention, due to limitations of imaging modalities and invasive tissue bio
Autor:
Shusuke Akamatsu, Kei Mizuno, Takayuki Sumiyoshi, Eijiro Nakamura, Noriaki Utsunomiya, Osamu Ogawa, Toshinari Yamasaki, Hiromasa Sakamoto, Masashi Takeda
Publikováno v:
Cancer Science
The therapeutic landscape of metastatic clear cell renal cell carcinoma (ccRCC) has rapidly expanded, and there is an urgent need to develop noninvasive biomarkers that can select an optimal therapy or evaluate the response in real time. To evaluate